DLA Piper LLP (US) offers a broad practice covering both contentious and non-contentious matters in the sector, including advice and representation in product liability, transactional, IP and regulatory matters. Global life sciences and healthcare co-chair Emilio Ragosa heads the team from Short Hills. Loren Brown co-ordinates mass tort and multidistrict litigation from New York, including product liability disputes involving allegations of contamination and personal injury, working with Boston-based Katie Insogna, who focuses on defense in product liability litigation for pharmaceutical, life science and medical device companies. In Philadelphia, IP advisor Raymond Miller covers patent prosecution and IP strategy, while Lauren Murdza acts for clients in life sciences transactions and license agreements. Based in Washington, DC, Vernessa Pollard chairs the FDA regulatory practice, advising medical device and technology clients on regulatory compliance during product development and promotion, while Andrew Gilbert advises on strategic matters and IP from New York.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Client satisfaction: Billing & efficiency
Testimonials
Collated independently by Legal 500 research team.
‘The team has been outstanding through the different stages of corporate development, including initial documents, seed funding, series A and B, and negotiations with strategic partners. I find them to be definitive sources and can trust their advice completely, including on personnel matters’
‘Andy Gilbert is the primary partner, and Sam Marll was the associate, but now a new partner. They have been 100% responsive and provide clear and timely, reliable responses to all issues.’
'Strong general knowledge of the field, multidisciplinary and with wide global presence – a true one-stop shop for a global life sciences client.'
Key clients
- Altesa BioSciences Inc.
- Bayer Corporation
- Bristol-Myers Squibb Company
- Cognition Therapeutics, Inc.
- DexCom, Inc.
- Elutia
- Johnson & Johnson
- Liquidia Corporation
- Novo Nordisk A/S
- Neurelis, Inc.
- Pfizer Inc.
- Sanofi
- Trustees of the University of Pennsylvania, The
Work highlights
Serves as co-national counsel for Sanofi in matters related to Zantac, a heartburn medication allegedly contaminated with NDMA, a possible carcinogen.
Managed Neurelis’ neuroscience IP portfolio – securing patents for FDA-approved VALTOCO and extending LOE, defending against generic challenge at the PTAB (IPRs) and in litigation (D. Ct. DE), and articulating strategy in diligence resulting in restructured licensing/acquisition offers that added over USD$500 million to the contemplated transaction.
Led a complex spin-out of University of Pennsylvania’s Wilson Lab into Gemma Biotherapeutics and Franklin Biolabs, negotiating multiple license agreements and sublicenses for programs underpinning a transaction exceeding USD$100 million.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Leading associates
Leading associates with regular involvement in their team's key work, and recognition from peers or clients as being ones to watch.
Practice head
Emilio Ragosa
Other key lawyers
Loren Brown; Katie Insogna; Ray Miller; Lauren Murdza; Vernessa Pollard; Andrew Gilbert; Sam Marll